B
Braidwell Portfolio holdings
AUM
$2.92B
1-Year Return
4.59%
This Quarter Return
-5.74%
1 Year Return
-4.59%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$3.16B
AUM Growth
+$104M
(+3.4%)
Cap. Flow
-$1.21B
Cap. Flow
% of AUM
-38.14%
Top 10 Holdings %
Top 10 Hldgs %
35.35%
Holding
100
New
14
Increased
28
Reduced
11
Closed
11
Top Buys
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
$25.9M |
| 2 |
89bio
ETNB
|
$24.6M |
| 3 |
Thermo Fisher Scientific
TMO
|
$24.5M |
| 4 |
Boston Scientific
BSX
|
$23.6M |
| 5 |
Immunocore
IMCR
|
$22.8M |
Top Sells
| 1 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$47.8M |
| 2 |
Biogen
BIIB
|
$34.7M |
| 3 |
Align Technology
ALGN
|
$30.2M |
| 4 |
Aclaris Therapeutics
ACRS
|
$30.1M |
| 5 |
Glaukos
GKOS
|
$26.2M |
Sector Composition
| 1 | Healthcare | 51.8% |
| 2 | Consumer Staples | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
89bio
ETNB
$1.28B
| $24.6M | 0.78% |
+1,590,387
| New | +$24.6M |
|
27
Penumbra
PEN
$10.8B
| $23.1M | 0.73% |
95,315
+29,471
| +45% | +$7.13M |
|
28
Guardant Health
GH
$7.59B
| $20.4M | 0.65% |
689,000
+419,000
| +155% | +$12.4M |
|
29
Lantheus
LNTH
$3.64B
| $20M | 0.63% |
+288,300
| New | +$20M |
|
30
Inspire Medical Systems
INSP
$2.55B
| $19.9M | 0.63% |
+100,300
| New | +$19.9M |
|
|
AXNX
31
DELISTED
Axonics, Inc. Common Stock
AXNX
| $19.9M | 0.63% |
354,527
-219,264
| -38% | -$12.3M |
|
32
HilleVax
HLVX
$105M
| $19.5M | 0.62% |
1,449,246
+200,000
| +16% | +$2.69M |
|
33
Mineralys Therapeutics
MLYS
$2.19B
| $19.2M | 0.61% |
2,023,900
+1,473,600
| +268% | +$14M |
|
34
Danaher
DHR
$142B
| $19.2M | 0.61% |
87,082
+24,591
| +39% | +$5.41M |
|
35
AnaptysBio
ANAB
$593M
| $18.9M | 0.6% |
1,049,823
-104,600
| -9% | -$1.88M |
|
36
Repligen
RGEN
$6.74B
| $18.8M | 0.6% |
118,400
+26,400
| +29% | +$4.2M |
|
37
Protagonist Therapeutics
PTGX
$3.68B
| $18.5M | 0.58% |
+1,109,150
| New | +$18.5M |
|
38
RAPT Therapeutics
RAPT
$207M
| $18M | 0.57% |
135,314
+12,264
| +10% | +$1.63M |
|
39
Cullinan Oncology
CGEM
$409M
| $17.3M | 0.55% |
1,908,865
| – | – |
|
40
Incyte
INCY
$16.7B
| $17M | 0.54% |
+294,900
| New | +$17M |
|
41
Transmedics
TMDX
$3.52B
| $16.8M | 0.53% |
+307,200
| New | +$16.8M |
|
|
DBVT
42
DBV Technologies
DBVT
$254M
| $16.5M | 0.52% |
1,210,779
| – | – |
|
43
Dyne Therapeutics
DYN
$1.87B
| $16.3M | 0.52% |
1,821,972
+444,100
| +32% | +$3.98M |
|
44
Terns Pharmaceuticals
TERN
$613M
| $14.3M | 0.45% |
2,840,052
+997,700
| +54% | +$5.02M |
|
45
Ironwood Pharmaceuticals
IRWD
$182M
| $13M | 0.41% |
+1,348,099
| New | +$13M |
|
46
Compass Therapeutics
CMPX
$467M
| $11.7M | 0.37% |
5,954,273
| – | – |
|
47
Enanta Pharmaceuticals
ENTA
$189M
| $11.6M | 0.37% |
1,038,310
| – | – |
|
48
Procept Biorobotics
PRCT
$2.13B
| $10.9M | 0.34% |
+331,061
| New | +$10.9M |
|
|
THRD
49
DELISTED
Third Harmonic Bio
THRD
| $10.6M | 0.33% |
+1,653,991
| New | +$10.6M |
|
50
Apogee Therapeutics
APGE
$2.21B
| $10.5M | 0.33% |
+491,113
| New | +$10.5M |
|